← Back to Search

Cancer Vaccine

PET Scan Agent for Prostate Cancer

Phase 2
Recruiting
Research Sponsored by AdventHealth
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
History of localized adenocarcinoma of the prostate with prior curative intent radical prostatectomy
Be older than 18 years old
Must not have
Patients currently receiving Androgen Deprivation Therapy (ADT)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights
No Placebo-Only Group

Summary

"This trial is testing a new radioactive agent called Flotufolastat F-18, used with PET imaging, to see if it can detect prostate cancer in patients with very low levels of PSA

Who is the study for?
This trial is for men who have had surgery to remove prostate cancer and now have low but rising PSA levels, suggesting the cancer might be coming back. Participants should not have received any other post-surgery cancer treatments.
What is being tested?
The study is testing Posluma (18F-rhPSMA-7.3), a radioactive agent used in PET scans, to see if it can detect returning prostate cancer at very low PSA levels after previous surgery.
What are the potential side effects?
As Posluma is a diagnostic agent used in imaging rather than a treatment drug, side effects are minimal but may include reactions at the injection site or rare allergic responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I had surgery to remove prostate cancer aimed at curing it.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently on hormone therapy for prostate cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cancer Detection Rate
Secondary study objectives
Adverse Events
Correlation with biopsy
Correlation with other imaging modalities
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Open Label Main ArmExperimental Treatment1 Intervention
Single Arm receiving PET scan with 18F-rhPSMA-7.3 (Posluma)

Find a Location

Who is running the clinical trial?

AdventHealthLead Sponsor
115 Previous Clinical Trials
31,522 Total Patients Enrolled
2 Trials studying Prostate Cancer
128 Patients Enrolled for Prostate Cancer
Blue Earth DiagnosticsIndustry Sponsor
41 Previous Clinical Trials
3,032 Total Patients Enrolled
10 Trials studying Prostate Cancer
1,253 Patients Enrolled for Prostate Cancer
~20 spots leftby Sep 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top